Ningbo Yaluo Venture Capital

Allor-Pha is a clinical-stage biopharmaceutical company based in Ningbo, China, focused on the development of innovative small molecule drugs for oncology and immunology. The company utilizes a proprietary drug discovery platform to target challenging biological pathways, including protein-protein interactions and specific phosphatases. Its lead program, ALR-101, is currently in Phase 1 clinical development for the treatment of advanced solid tumors. Founded by experienced pharmaceutical industry veterans, Allor-Pha integrates structure-based drug design with advanced medicinal chemistry. The company has secured significant venture capital funding to advance its pipeline of precision medicines toward commercialization. Allor-Pha maintains research and development facilities in both Ningbo and Shanghai to support its integrated drug discovery efforts.